144 results about "Ingestion" patented technology

The invention relates to the technical field of medical apparatus and instruments, and discloses a long-acting gastric retention drug delivery device which can enter the stomach in an oral self-ingestion mode, further realizes size change through expansion of an elastic assembly, enhances the mechanical strength of the elastic assembly through a water-induced hard polymer, and avoids extrusion deformation and emptying through the pylorus of the stomach. The device comprises a medicine carrying assembly, an elastic assembly and a connecting assembly, the medicine carrying assembly comprises a plurality of medicine carrying pieces, and each medicine carrying piece is provided with a medicine carrying cavity. The elastic assembly comprises a plurality of elastic pieces, and the first ends of the elastic pieces are connected with one another, so that the elastic assembly is in a star shape in the unfolded state. The outer layer of the elastic assembly is coated with a reinforcing film, and the reinforcing film is formed by curing a water-hardened polymer and can be gradually converted into rigidity from flexibility in a water-based environment. The connecting assembly comprises a plurality of connecting pieces, the second end of one elastic piece is connected with one medicine carrying piece through one connecting piece, and the connecting pieces are decomposed under preset conditions, so that the medicine carrying pieces and the elastic assembly are separated and discharged out of the body in a non-invasive mode.

The invention discloses a composite microbial preparation for treating obesity of pet dogs and application of the composite microbial preparation, and belongs to the technical field of microbial preparations. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146, and the preservation number of the lactobacillus reuteri GBW1146 is CGMCC (China General Microbiological Culture Collection Center) No. 34455. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146. The compound microbial preparation can remarkably reduce digestion and absorption of intestinal tracts of dogs on fat and reduce triglyceride and cholesterol levels in blood, so that the average food intake and average calorie consumption of the dogs are reduced, and finally the effect of reducing obesity of the pets is achieved. The compound microbial preparation provided by the invention enhances the competitiveness of the pet feed additive and series products thereof in China in the international market, and has a wide application prospect.

The invention relates to the technical field of food nutrition and health care and biological medicines, in particular to application of beta-1, 3 / alpha-1, 3-glucan in preparation of medicines for treating and / or preventing obesity and / or body weight super-severe illness and digestion-aiding health food. According to the experimental results, high-glucose and high-fat rats are continuously fed in the stomach for 8 weeks, and the food intake can be effectively reduced and the body weight can be reduced through preventive administration; the conclusion that beta-1, 3 / alpha-1, 3-glucan has the digestion-aiding health-care food function can be obtained according to the requirements of'health-care food function inspection and evaluation method (2023 edition) by combining the research results that beta-1, 3 / alpha-1, 3-glucan has the stimulation effect on small intestine peristalsis, promotes the growth of intestinal beneficial bacteria and regulates intestinal health in the existing research. The invention provides a new direction for preparing the medicine for treating and / or preventing obesity and / or body weight super-severe illness and health-care food beneficial to digestion.

Doubly labeled water with enhanced protocol. One embodiment is a method including providing, to a user, a doubly labeled water (DLW) dose for the user to ingest, the DLW dose including deuterium and oxygen-18, wherein an amount of the deuterium is less than 0.12 grams per kilogram (g / kg) of body water of the user, and wherein an amount of the oxygen-18 is less than 0.18 g / kg of body water of the user. The method also includes receiving, from the user, a non-cooled shipment of urine samples collected in connection with ingestion of the DLW dose, wherein the urine samples remain uncooled after collection and during transit for a period of up to 24 days. The method further includes processing the urine samples with a liquid water isotope analyzer to determine one or more metabolic parameters of the user.

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The utility model discloses an arma chinensis fallou feeding device, which relates to the field of insect feeding equipment, and comprises a feeding box, a liquid storage container and a liquid suction feeding part, the top of the feeding box is provided with a liquid inlet, the bottom of the liquid storage container is connected with a liquid guide pipe, the liquid guide pipe is communicated with the liquid inlet, and the liquid guide pipe is provided with a flow regulator; the liquid suction feeding part is vertically arranged in the feeding box, and the bottom of the liquid suction feeding part is in contact with feeding liquid in the feeding box and adsorbs the feeding liquid; by arranging the liquid storage container and the liquid guide pipe, feeding liquid can be continuously supplied to the feeding box, the liquid suction feeding part is arranged to adsorb the feeding liquid for arma chinensis to suck, and the feeding speed of the feeding liquid is adjusted through the flow adjuster, so that the feeding speed of the arma chinensis and the feeding speed of the feeding liquid are balanced; the method that in the prior art, soaked sponge, cotton and the like are placed above a rearing cage gauze for feeding is replaced, the feeding difficulty is greatly reduced, the feeding operation time of a breeder is saved, and the bug breeding technology is standardized.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The utility model discloses a non-toppling type confrontable abundant feeding device for herbivorous animals, which comprises a non-toppling type base with a hemispherical structure, a stand column shaft is vertically arranged at the center of the surface of the non-toppling type base, and the stand column shaft is detachably connected with the non-toppling type base; the stand column shaft is sleeved with a feeding barrel, and food leaking holes are formed in the outer wall of the feeding barrel. A plurality of branch-shaped stand column suites are further arranged on the stand column shaft above the feeding barrel. According to the feeding device, the non-toppling confrontable base is designed to be of a semi-spherical structure and has the function similar to a tumbler, the whole feeding device can swing back and forth, and when an animal pokes the abundant feeding device to swing, the semi-spherical non-toppling base can also drive the stand column shaft to finally return to the vertical position; the flexibility and interestingness of animal ingestion can be improved, the activities of animals are effectively enriched, the occurrence of engraving behaviors is reduced, and the animal welfare is improved.

Jaw health systems and methods are described in which headphone devices are used to generate metrics related to the jaw health of a user. In one aspect, headphone devices worn on either side of the jaw may each determine the number of bites and chews of a user during an ingestion process and may then generate an imbalance metric. In one aspect, the headphone devices may be used to determine a food or substance toughness during the ingestion process.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

The present disclosure provides a biodegradable device that is administered to a patient in the form of a compact, ingestible package. The device is self-expandable within the stomach upon contact with liquid to assume an expanded bulk structure within the stomach. The device has a folded configuration that facilitates ingestion by the patient and is designed to unfold and self-expand within the stomach upon ingestion due to expansion of a plurality of expandable cells comprising one or more gel-forming materials. The present disclosure provides such a device, methods of manufacturing the same, and building blocks thereof.

The present invention addresses the problem of providing a novel functionality of a Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623), and a method for producing the same, and more particularly, to provide a novel functionality of a Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623). A composition to be ingested by healthy neonates or infants who are born for a full month contains, as an active ingredient, one or more species selected from the group consisting of a cell of Bifidobacterium longum subsp. Infantis M-63 (NITE BP-02623), a culture of the cell, and a treated product of the cell. The composition is used for promoting colonization of bifidobacterium bacteria in intestinal flora, promoting maturation of intestinal function, inhibiting milk spilling or regulating immune function.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

The present invention relates to a colon cleansing composition with improved ease of administration. The composition minimizes side effects caused by excessive ingredient content in conventional colonic laxatives while providing equivalent or superior intestinal cleansing efficacy, thereby remarkably improving patient compliance and ingestion convenience. In addition, as an uncoated tablet requiring no separate coating processes, a preparation that maintains the quality of tablets such as rapid disintegration and does not have a bitter taste can be provided. The present invention provides a pharmaceutical formulation comprising the colon cleansing composition with improved ease of administration and a method for colon cleansing using the formulation, thereby realizing a patient-centered colon cleansing process and ultimately greatly contributing to the improvement of colonoscopy quality.

This invention discloses a traditional Chinese medicine composition with calming and sleep-aiding effects and its preparation method, relating to the field of pharmaceutical technology. The traditional Chinese medicine composition with calming and sleep-aiding effects comprises the following raw materials in parts by weight: 15-25 parts of vetiver volatile oil, 15-25 parts of valerian volatile oil, 8-12 parts of sandalwood volatile oil, 8-12 parts of cyperus rotundus volatile oil, 8-12 parts of albizia julibrissin bark volatile oil, 5-8 parts of orange blossom volatile oil, 8-12 parts of polygala tenuifolia volatile oil, 8-12 parts of schisandra chinensis volatile oil, 5-8 parts of jasmine volatile oil, and 500-520 parts of fractionated coconut oil. This invention also provides a method for preparing the traditional Chinese medicine composition with calming and sleep-aiding effects, effectively solving the problems of existing sleep aid products that easily cause liver and kidney metabolic burden, gastrointestinal irritation, uncontrollable dosage of active ingredients, and ingestion of ineffective ingredients.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The invention discloses a method for measuring the feeding behavior of adult zebrafish, which comprises the following steps: S1, experimental fish preparation: selecting healthy female TU zebrafish at the age of six months, and dividing the female TU zebrafish into a control group and an exposure group after the female TU zebrafish adapts to a system water environment; s2, long-term drug exposure: using system water in a control group, using system water containing a target drug in an exposure group, continuously exposing for 28 days, replacing exposure liquid every day and maintaining a constant environmental condition; s3, food intake behavior determination: transferring the single zebra fish to an independent water tank, putting quantitative feed after adaptation, recording the food intake process through a behavior analysis system, and analyzing the first food intake time, the incomplete food intake proportion and the total food intake duration; and S4, performing data statistics: performing difference significance analysis by adopting SPSS software, and judging the influence of the medicine on the ingestion behavior. The invention aims to detect the potential influence of long-term exposure of environment-related concentration drugs on the ingestion function of fishes, and is suitable for evaluating the interference effect of long-term exposure of low-concentration drugs on the ingestion function of aquatic organisms.

The invention discloses a non-sterilization type mildew-proof and antibacterial material capable of dynamically responding to thallus proliferation as well as a preparation method and application of the non-sterilization type mildew-proof and antibacterial material. The material comprises polyvinyl alcohol, carboxymethyl cellulose or a salt thereof and metal ions, and the polyvinyl alcohol, the carboxymethyl cellulose or the salt thereof are bridged through the metal ions; the metal ions comprise Li < + >. The material disclosed by the invention takes Na < + > released by thallus proliferation as a signal medium, releases Li < + > as required through a coordination-dissociation process, and further induces thallus cells to actively ingest Li < + > through metabolic deception of occupying a potassium ion channel by utilizing a hydration radius of Li < + > similar to K < + > according to the metabolic demand of sodium excretion and potassium ingestion in the thallus proliferation process; on one hand, bacterial cell replication lacks essential nutrient substance K < + >, and finally gradually declines; on the other hand, protein space conformation is changed and inactivated by capturing water molecules of intracellular protein, and the two aspects have a synergistic effect, so that the efficient mildew-proof and antibacterial effects of Li < + > at low concentration can be realized, and the effect is lasting.

Described herein is a controlled release pet food composition comprising: a matrix comprising: a fibrous component comprising a high solubility fiber source and a low solubility fiber source, and a polyphenol source; wherein the matrix is adapted to deliver the polyphenol source to the lower gastrointestinal (GI) tract of a mammal upon uptake by the mammal. Methods of making and using these compositions are also described.

Introduced herein is an ingestible device capable of delivering a drug directly to tissues along the digestive tract. Administration of the drug stored in the ingestible device can be achieved through a combination of features. The ingestible device can include a plunging mechanism to which a needle is connected and a dissolvable trigger mechanism that holds the plunging mechanism in a first position. After ingestion, the trigger mechanism can be exposed to bodily fluids to cause dissolution. When the trigger mechanism dissolves, the plunging mechanism can move from the first position to a second position, thereby extending the needle into the tissue in which the ingestible device is housed. Second, the needle can also dissolve upon exposure to bodily fluids to ensure safe passage of the ingestible device through the digestive tract.

The invention relates to the technical field of carp culture, in particular to a culture method for carps in a high water temperature period and application of the culture method. According to the method, a breeding period is divided into an earlier stage, a high water temperature period and a later stage according to water temperature, and floating expanded compound feed, granular compound feed and high-energy floating expanded compound feed are fed respectively; the feeding rate, feeding times and dissolved oxygen of the three stages are controlled. The invention further provides application based on the breeding method. The breeding period is divided according to the water temperature, different feeds are fed in stages, and the feeding rate, the feeding frequency and the dissolved oxygen amount are controlled in stages, so that the damage and death conditions caused by ingestion of the carps in the high-water-temperature period are reduced; the carps can grow quickly in the early stage, liver and gall function health care is conducted, good ingestion and growth speed is kept in the high-water-temperature period, and high-speed growth and weight gaining are conducted in the later stage; the survival rate in the high-water-temperature period, the weight increment and the growth speed in the whole process are remarkably improved, and the problems that the growth performance and the survival rate of carps are low when the carps are cultured in the high-water-temperature period in the southwest region are solved.

A health analysis system and method configured to base sensor measurements on detection of ingestion of a medication by a patient. The health analysis system receives an indicator collected by a first sensor associated to the patient. The indicator identifies a first adherence event at a first indicator time indicating at least a first medication was ingested by the patient. In response to detection of the indicator, first physiological data of the patient is received which was collected by a second sensor. A first wellness indicator is predicted based on the first physiological data of the patient.

The invention provides a pellet feed precise feeding method and system based on animal information feedback, and relates to the technical field of animal feeding. The method comprises the following steps: when an animal reaches an entrance of a feeding area, determining weight information of the animal fed this time through a weighing sensor, and storing the weight information; after the animal arrives at the feeding point, collecting animal identity information according to the ear tag information of the animal; determining the target feeding amount of the feeding, and performing quantitative feeding; determining the weight of the residual feed for feeding this time; determining the actual feed intake of the feeding; and updating the animal identity information. According to the invention, the target feeding amount can be determined based on the animal weight information and the animal identity information, and quantitative feeding is carried out, so that the animal identity information is updated. According to the animal feeding method, the target feeding amount can be dynamically adjusted according to the ingestion condition and weight change of animals, the feed ratio is optimized in an auxiliary mode, the target feeding amount and the accuracy and pertinence of feed ratio determination are improved, and the animal feeding efficiency is improved.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The present invention relates to the field of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood tissue barrier shielded organs having a large number of populations of post-mitotic neurons, such as organs derived from neural tubes, including the central nervous system and the eye. The disclosed methods and compositions involve topically applying into such organs a combination of an effector component that targets a biological target in a cell, and a saponin component that promotes effective ingestion of the effector component into the cell and / or enhances effective path steering of the effector component within the cell in which the biological target is present. For example, the effector component may be an oligonucleotide therapeutic agent targeting gene products associated with CNS and / or disorders of the eye. Due to the cellular uptake stimulating effect and / or endosomal escape enhancing effect of the saponin component, the neuropharmaceutical and ophthalmic compositions presented herein for topical administration into the CNS and / or eye, respectively, may be formulated with lower concentrations of effector components and / or in smaller volumes, this brings safety benefits to the neurons and the comfort of the patient.

Beta-hydroxybutyrate compositions formulated for ingestion by oral delivery as a beverage, or as a dietary supplement for addition to water or beverage, include a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate. The beta-hydroxybutyrate composition can include enantiomerically pure R-beta-hydroxybutyrate or a non-racemic mixture enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate. Alternatively, the beta-hydroxybutyrate composition can include enantiomerically pure S-beta-hydroxybutyrate or a non-racemic mixture enriched in S-beta-hydroxybutyrate relative to R-beta-hydroxybutyrate. Alternatively, the beta-hydroxybutyrate composition can include a racemic mixture of R-beta-hydroxybutyrate and R-beta-hydroxybutyrate. The beta-hydroxybutyrate compositions comprise beta-hydroxybutyric acid and optionally one or more beta-hydroxybutyrate salts or esters.

The invention discloses a method for evaluating spice regulation satiety based on animal behavioristics, which comprises the following steps of: establishing an appetite intervention model (intragastric spices or medicines), and adopting a modified elevated cross labyrinth device (comprising a detachable trough and a sensor); synchronously recording the incubation period T of the experimental subject in contact with the food for the first time, the number F of times of food area exploration and the food intake I, and calculating the correlation coefficient r of the behavior parameters and the food intake through a Pearson correlation coefficient formula. When rgt; and when 0.6, judging that the behavior change can reflect the satiety state. The method realizes multi-dimensional parameter cross validation of appetite evaluation, and is suitable for functional food and medicine development.